Ionis Pharmaceuticals, Inc announced that its Phase III cardiovascular outcome clinical trial "Cardio-Ttransform" for the drug Eplontersen failed to meet its primary endpoint in the analysis at week 140.
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
The trial aims to evaluate the cardiovascular benefits of Eplontersen in specific patient populations. Although it did not meet the prespecified primary endpoint, the company stated that the comprehensive data collected during the trial is undergoing in-depth analysis to assess the overall benefit-risk profile of the drug and to inform future development decisions.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now！
You may also like
Correction to Jersey Mike's Subs Rating
Dow Jones•2026/09/29 19:09
SEC Clears Tesla's New Retail Voting System. What Changes for Investors?
BeInCrypto•2026/09/29 18:48
GFL Environmental Declares Q3 Dividend of $0.0169
MT newswire•2026/09/29 18:41
Update: Equities Drop Intraday, Yields Rise as Traders Parse Macro Data
MT newswire•2026/09/29 18:25
Crypto prices
More
Bitcoin
BTC
$83,566.61
-0.16%
Ethereum
ETH
$2,695.88
+0.38%
Tether USDt
USDT
$0.9996
+0.00%
BNB
BNB
$755.7
-1.46%
XRP
XRP
$1.5
+0.29%
USDC
USDC
$0.9999
-0.00%
Solana
SOL
$119.37
+0.20%
TRON
TRX
$0.3352
-0.32%
Zcash
ZEC
$1,426.26
-4.10%
Hyperliquid
HYPE
$86.5
-1.87%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now